|
Sharkey, Robert M; Brenner, Arnold; Burton, Jack et al. (2003) Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med 44:2000-18
|
|
Goldenberg, D M (2001) The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol 39:195-201
|
|
Tsai, D E; Schuster, S J; Matthies, A et al. (2000) Progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem-cell transplantation: changing the natural history with monoclonal antibody therapy. Clin Lymphoma 1:62-6
|
|
Juweid, M E; Stadtmauer, E; Hajjar, G et al. (1999) Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res 5:3292s-3303s
|
|
Goldenberg, D M; Juweid, M; Dunn, R M et al. (1997) Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy. J Nucl Med Technol 25:18-23; quiz 34
|
